Publications by authors named "Gerry Everlof"

Claim this Profile
E
Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation.
Murugaiah A M Subbaiah, Naveen Manjunath, Thangeswaran Ramar, Mathiazhagan Annadurai, Naveen Kumar Dhondi, Gerry Everlof

J Med Chem· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydrolysis of cellulose acetate phthalate and hydroxypropyl methylcellulose phthalate in amorphous solid dispersions.
Jinghan Li, Dongyue Yu, Chaowang Zeng, Laura I Mosquera-Giraldo, Gerry Everlof

J Pharm Sci· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balanced Permeability Index: A Multiparameter Index for Improved In Vitro Permeability.
Dahlia R Weiss, Javier L Baylon, Ethan D Evans, Anthony Paiva, Gerry Everlof

ACS Med Chem Lett· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1-pyrazol-1-yl)methyl)phosphonate (BMS-820132).
Yan Shi, Ying Wang, Wei Meng, Robert P Brigance, Denis E Ryono, Gerry Everlof

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype.
Matthew D Hill, Claude Quesnelle, John Tokarski, Haiquan Fang, Carolynn Fanslau, Gerry Everlof

Bioorg Med Chem Lett· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases.
Peter T W Cheng, Robert F Kaltenbach, Hao Zhang, Jun Shi, Shiwei Tao, Gerry Everlof

J Med Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.
Ashvinikumar V Gavai, Derek Norris, George Delucca, David Tortolani, John S Tokarski, Gerry Everlof

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of BET inhibitors as potential treatments for cancer: A search for structural diversity.
Matthew D Hill, Haiquan Fang, John Tokarski, Carolynn Fanslau, Zuzana Haarhoff, Gerry Everlof

Bioorg Med Chem Lett· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Mohammed N Meah, Jennifer Raftis, Simon J Wilson, Vidya Perera, Samira M Garonzik, J Gerry Everlof

Arterioscler Thromb Vasc Biol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
Victor R Guarino, Richard E Olson, J Gerry Everlof, Nenghui Wang, Ivar McDonald

Bioorg Med Chem Lett· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor.
Chunjian Liu, James Lin, John Hynes, Hong Wu, Stephen T Wrobleski, Gerry Everlof

J Med Chem· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.
Ashvinikumar V Gavai, Claude Quesnelle, Derek Norris, Wen-Ching Han, Patrice Gill, Gerry Everlof

ACS Med Chem Lett· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-Benzothiazole-7-hydroxyindolinyl diaryl ureas are potent P2Y1 antagonists with favorable pharmacokinetics: low clearance and small volume of distribution.
Jennifer X Qiao, Tammy C Wang, Sheldon Hiebert, Carol H Hu, William A Schumacher, Gerry Everlof

ChemMedChem· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Dean A Wacker, Ying Wang, Matthias Broekema, Karen Rossi, Steven O'Connor, Gerry Everlof

J Med Chem· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
Bruce A Ellsworth, Philip M Sher, Ximao Wu, Gang Wu, Richard B Sulsky, Gerry G Everlof

J Med Chem· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.
Tammy C Wang, Jennifer X Qiao, Charles G Clark, Ji Jua, Laura A Price, Gerry Everlof

Bioorg Med Chem Lett· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor.
Chunjian Liu, James Lin, Gerry Everlof, Christoph Gesenberg, Hongjian Zhang

Bioorg Med Chem Lett· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-dependent tumor necrosis factor-alpha antagonists.
Matthew E Voss, Percy H Carter, Andrew J Tebben, Peggy A Scherle, Gregory D Brown, J Gerry Everlof

Bioorg Med Chem Lett· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymorphism of roxifiban.
Michael B Maurin, Rodney D Vickery, Shelley R Rabel, Susan M Rowe, J Gerry Everlof

J Pharm Sci· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis